THE GENCARO TEST Trademark

Trademark Overview


On Friday, June 25, 2021, a trademark application was filed for THE GENCARO TEST with the United States Patent and Trademark Office. The USPTO has given the THE GENCARO TEST trademark a serial number of 90795317. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, December 26, 2024. This trademark is owned by ARCA biopharma, Inc.. The THE GENCARO TEST trademark is filed in the Pharmaceutical Products, Medical Instrument Products, and Medical & Beauty Services & Agricultural Services categories with the following description:

Medical diagnostic test kits comprised of medical diagnostic reagents and assays for use in identifying common genetic variations in receptors in the cardiovascular system; Medical diagnostic assays for use in testing body fluids to determine appropriate drug treatment for medical patients

Medical diagnostic testing services for others

Medical test kits comprising a medical diagnostic testing instrument for obtaining and analyzing DNA samples from bodily fluid samples, blood samples, buccal swabs and other human tissues for use in identifying common genetic variations in receptors in the cardiovascular system; Medical testing instruments for use in identifying common genetic variations in receptors in the cardiovascular system
the gencaro test

General Information


Serial Number90795317
Word MarkTHE GENCARO TEST
Filing DateFriday, June 25, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, December 26, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 22, 2022

Trademark Statements


Goods and ServicesMedical diagnostic test kits comprised of medical diagnostic reagents and assays for use in identifying common genetic variations in receptors in the cardiovascular system; Medical diagnostic assays for use in testing body fluids to determine appropriate drug treatment for medical patients
Goods and ServicesMedical diagnostic testing services for others
NOT AVAILABLE"TEST"
Goods and ServicesMedical test kits comprising a medical diagnostic testing instrument for obtaining and analyzing DNA samples from bodily fluid samples, blood samples, buccal swabs and other human tissues for use in identifying common genetic variations in receptors in the cardiovascular system; Medical testing instruments for use in identifying common genetic variations in receptors in the cardiovascular system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 9, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, September 9, 2021
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 9, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGENVARA BIOPHARMA, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressWESTMINSTER, CO 80021

Party NameARCA Biopharma, Inc
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWestminster, CO 80020

Party NameARCA biopharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWestminster, CO 80020

Trademark Events


Event DateEvent Description
Friday, March 18, 2022NON-FINAL ACTION WRITTEN
Tuesday, June 29, 2021NEW APPLICATION ENTERED
Thursday, September 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 17, 2022ASSIGNED TO EXAMINER
Friday, March 18, 2022NON-FINAL ACTION E-MAILED
Friday, March 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 19, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, September 19, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 17, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 2, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 22, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 22, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 11, 2023SOU EXTENSION 1 FILED
Tuesday, July 11, 2023SOU EXTENSION 1 GRANTED
Thursday, July 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 9, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 9, 2024SOU EXTENSION 2 FILED
Tuesday, January 9, 2024SOU EXTENSION 2 GRANTED
Thursday, January 11, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 21, 2024SOU EXTENSION 3 FILED
Friday, June 21, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024SOU EXTENSION 3 GRANTED
Monday, August 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 19, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, December 19, 2024SOU EXTENSION 4 FILED
Thursday, December 19, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, December 25, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, December 27, 2024SOU EXTENSION 4 GRANTED
Friday, December 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED